神經退化疾病的交易分析

神經退化疾病的交易分析 是由出版商PharmaVentures Ltd在2010年07月所出版的。 這份英文市場調查報告書價格從美金3344起跳。

簡介

本報告，同時彙整阿茲海默症•帕金森氏症•多發性硬化症•癲癇•偏頭痛等神經退化疾病的概要與市場規模、目前的療法與開發中的產品動向、種類別•開發階段別•產品別的交易動向，由下列摘要形式闡述。

第1章 神經退化疾病的簡介

• 概要
• 神經退化疾病交易的整體動向
  • 其他治療領域與比較
  • 交易件數
  • 交易額
• 主要參與企業
• 領域別交易
• 金融危機的影響
• 品牌忠誠度

第2章 阿茲海默症

• 概要
  • 免疫學
  • 市場規模
  • 目前的療法
  • 未來的療法：開發中的產品
• 阿茲海默症的交易動向
  • 概要
  • 種類別
  • 開發階段別
  • 產品別
  • 參與企業

第3章 帕金森氏症

• 概要
  • 免疫學
  • 市場規模
  • 目前的療法
  • 未來的療法：開發中的產品
• 帕金森氏症的交易動向
  • 概要
  • 種類別
  • 開發階段別
  • 產品別
  • 參與企業

第4章 多發性硬化症

• 概要
  • 免疫學
  • 市場規模
  • 目前的療法
  • 未來的療法：開發中的產品
• 多發性硬化症的交易動向
  • 概要
  • 種類別
  • 開發階段別
  • 產品別
  • 參與企業

第5章 癲癇

• 概要
  • 免疫學
  • 市場規模
  • 目前的療法
  • 未來的療法：開發中的產品
• 癲癇的交易動向
  • 種類別
  • 開發階段別
  • 產品別
  • 參與企業

第6章 偏頭痛

• 概要
  • 免疫學
  • 市場規模
  • 目前的療法
  • 未來的療法：開發中的產品
• 偏頭痛的交易動向
  • 種類別
  • 開發階段別
  • 產品別
  • 參與企業

第7章 結論

第8章 附錄1：阿茲海默症

第9章 附錄2：帕金森氏症

第10章 附錄3：多發性硬化症

第11章 附錄4：癲癇

第12章 附錄4：偏頭痛

圖表

目錄

Abstract

This new report follows the highly acclaimed and popular report series on key deal making therapy areas. It focuses on the five major neurodegenerative diseases:

• Alzheimer' s disease
• Parkinson' s disease
• Multiple sclerosis
• Epilepsy
• Migraine

The report contains analysis of deals by deal and product type, number of deals year on year and the value and stage of development of these deals. It looks at the key players and includes case studies of the key deals being made within the five neurodegenerative diseases.

All deal data in this report are taken from the world-leading PharmaDealsR v2 Agreements database.

Table of Contents

1 Introduction to neurodegenerative diseases

• 1.1 Overview
• 1.2 Overall trends in neurodegenerative disease deals
  • 1.2.1 Comparison with other therapy areas
  • 1.2.2 Number of deals
  • 1.2.3 Value of deals
• 1.3 Key players
• 1.4 Deals by territory
• 1.5 Impact of the ' credit crunch'
• 1.6 Royalties

2 Alzheimer' s disease

• 2.1 Overview
  • 2.1.1 Epidemiology
  • 2.1.2 Market size
  • 2.1.3 Current therapies
  • 2.1.4 Future treatments - products in development
• 2.2 Trends in deal making in Alzheimer' s disease
  • 2.2.1 Overview
  • 2.2.2 Analysis of deals by deal type
  • 2.2.3 Deals by stage of development
  • 2.2.4 Deals by product type
  • 2.2.5 Key players

3 Parkinson' s Disease

• 3.1 Overview
  • 3.1.1 Epidemiology
  • 3.1.2 Market size and trends
  • 3.1.3 Current therapies
  • 3.1.4 Future treatments - products in development
• 3.2 Trends in deal making in Parkinson' s disease
  • 3.2.1 Analysis of deals by deal type
  • 3.2.2 Deals by stage of development
  • 3.2.3 Deals by product type
  • 3.2.4 Key players

4 Multiple sclerosis

• 4.1 Overview
  • 4.1.1 Epidemiology
  • 4.1.2 Market size and trends
  • 4.1.3 Current therapies
  • 4.1.4 Future treatments - products in development
• 4.2 Trends in deal making in Multiple sclerosis
  • 4.2.1 Analysis of deals by deal type
  • 4.2.2 Deals by stage of development
  • 4.2.3 Deals by product type
  • 4.2.4 Key players

5 Epilepsy

• 5.1 Overview
  • 5.1.1 Epidemiology
  • 4.1.2 Market size and trends
  • 4.1.3 Current therapies
  • 5.1.4 Future treatments - products in development
• 5.2 Trends in deal making in Epilepsy
  • 5.2.1 Analysis of deals by deal type
  • 5.2.2 Deals by stage of development
  • 5.2.3 Key players

6 Migraine

• 6.1 Overview
  • 6.1.1 Epidemiology
  • 6.1.2 Market size and trends
  • 6.1.3 Current therapies
  • 6.1.4 Future treatments - products in development
• 6.2 Trends in deal making in Migraine
  • 6.2.1 Analysis of deals by deal type
  • 6.2.2 Deals by stage of development
  • 6.2.3 Key players

7 Conclusions

8 Appendix 1: Alzheimer' s disease deals

• 8.1 J&J and Elan
• 8.2 TorreyPines and Eisai
• 8.3 Medivation and Pfizer
• 8.4 Myriad Genetics and Lundbeck
• 8.5 CoMentis and Astellas
• 8.6 Ablynx and Boehringer

9 Appendix 2: Parkinson' s Disease deals

• 9.1 Newron Pharmaceuticals and Serono
• 9.2 Biovail and Acadia

10 Appendix 3: Multiple sclerosis deals

• 10.1 Facet Biotech and Abbott
• 10.2 Bayer Schering and Genzyme
• 10.3 BioMS Medical Corp and Eli Lilly
• 10.4 Acorda Therapeutics and Biogen Idec
• 10.5 Fast Forward LLC and Merck Serono

11 Appendix 4: Epilepsy deals

• 11.1 Valeant and GSK
• 11.2 BIAL Group and Separacor

12 Appendix 4: Migraine deals

• 12.1 Pozen and GSK

Tables

• 1 Prevalence rates for dementia by age group
• 2 Main drugs currently marketed for AD
• 3 Products in Phase III development for AD
• 4 Selected AD deals
• 5 AD drugs providing symptomatic relief
• 6 Potentially disease-modifying AD agents
• 7 Diagnostics
• 8 Top AD dealmakers (1996 to 2009)
• 9 Pfizer/Wyeth late stage AD pipeline
• 10 Top AD principal/orginator organisations (1996 to 2009)
• 11 Elan' s involvement in later stage AD drugs
• 12 Products in Phase III development for PD
• 13 Top PD dealmakers (1996 to 2009)
• 14 Top PD principal/originator organisations (1996 to 2009)
• 18 Biogen Idec' s MS pipeline portfolio
• 19 Products in later stage development for epilepsy
• 20 Top epilepsy dealmakers (1996 to 2009)
• 21 Top epilepsy principal/originator organisations (1996 to 2009)
• 22 Products in later stage development for migraine
• 23 Top migraine dealmakers (1996 to 2009)

Figures

• 1 Deal intensity by therapeutic area (1996 to 2009)
• 2 Number of deals in five neurodegenerative disease areas (1996 to 2009)
• 3 Value of deals in five neurodegenerative disease areas (1996 to 2009)
• 3 Value of deals in five neurodegenerative disease areas (1996 to 2009)
• 4 Number of deals by territory in five neurodegenerative disease areas (1996 to 2009)
• 5 Impact of the credit crunch on deal-making
• 6 Disclosed royalty rates for selected neurodegenerative diseases deals
• 7 2009 worldwide sales of AD drugs (US$ M)
• 8 total AD deals by deal type
• 9 Year on year analysis by deal type
• 10 Deal type by value
• 11 Number of AD deals by stage of development
• 12 Average value of AD deals by stage of development
• 13 Total PD deals by deal type
• 14 Year on year analysis by deal type
• 15 Deal type by value
• 16 Number of PD deals by stage of development
• 17 Average value of PD deals by stage of development
• 18 2009 worldwide sales of MS drugs (IUS$M)
• 19 Total MS deals by deal type
• 20 Year on year analysis by deal type
• 21 Deal type by value
• 22 Number of MS deals by stage of development
• 23 Average value of MS deals by stage of development
• 24 Total epilepsy deals by deal type
• 25 Deal type by value
• 26 Number of epilepsy deals by stage of development
• 27 Total migraine deals by deal type
• 28 Number of migraine deals by stage of development
• 29 Average value of migraine deals by stage of development

相關商品

神經疾病相關市場調查報告書

中樞神經系統(CNS)的罕見疾病治療市場(∼2017年):AMR101和ACR16等新藥提供治療可供選擇，支援亨丁頓舞蹈症市場區隔
Orphan Diseases Therapeutics in CNS to 2017 - Novel Agents such as AMR101 and ACR16 to Provide Treatment Options and Boost the Huntington's Disease Segment
價格 : US $ 3500
出版日期 : 2012年04月

神經保護：醫療藥品・市場・企業
Neuroprotection - Drugs, Markets and Companies
價格 : US $ 5000
出版日期 : 2012年04月

阿茲海默症：新藥・市場・企業
Alzheimer disease - new drugs, markets and companies
價格 : US $ 3500
出版日期 : 2012年04月

PharmaVentures Ltd發行的製藥相關市場調查報告書

權利金授權比率報告2012：醫療部門之全面評估

The Royalty Rate Report 2012: A Comprehensive Assessment of Valuation in the Pharmaceutical Sector

價格 : US $ 8005

出版日期 : 2012年03月

重要交易動向：癌（2011年）

Essential Deal Trends: Oncology 2011

價格 : US $ 2395

出版日期 : 2011年10月

疫苗領域的交易分析

Analysis of Deal Making in Vaccines

價格 : US $ 3344

出版日期 : 2010年11月

Email Alert(Email 通知) - 最新市場調查報告書

GII 將每天定期更新最新市場調查報書資訊，選擇您有興趣的市場分類，我們將用Email的方式讓您收到最新訊息!